In 2005 the pharmaceutical company GlaxoSmithKline:
shipped 126 million preferentially-priced tablets for treating HIV/AIDS to developing countries - 90% more than 2004
stepped up a drive on ethics and compliance, including the appointment of a full-time compliance officer in each of GSK’s major business units
achieved 5-year environmental targets in six areas, including energy and water consumption, and made substantial progress in other areas even though some demanding targets were missed.
These facts are revealed in GSK’s latest corporate responsibility report, published on its website at:
www.gsk.com/responsibility/cr_report_2005/index.htm
The report covers how GSK addresses and manages issues arising from its business activities, reflecting its belief that good corporate responsibility performance supports the business strategy - protecting and enhancing relationships and its reputation with doctors, governments and patients.
GSK’s core business - the research and production of medicines - makes a valuable contribution to society. Its medicines are literally life-saving for many people. But GSK believes it needs to address complex issues associated with the research, manufacture and sale of medicines - from the publication of research results and marketing practices of pharmaceutical sales representatives, to the use of animals in research and the environmental impacts of manufacturing processes.
Feedback on this report can be sent via the GlaxoSmithKline listing on CorporateRegister.com available here
www.corporateregister.com/data/report.pl?num=15002
Visit www.CorporateRegister.com to access this publication together with a further 10,000 corporate non-financial reports.
